[Adjuvant study of high-risk muscle invasive urothelial carcinoma : Open-label, multicenter, randomized phase III study with atezolizumab (anti-PD-L1 antibody) as adjuvant therapy compared with observation in patients with high-risk muscle invasive urothelial carcinoma after surgical resection (IMvigor010)- study AB 53/15 of the AUO].

Urologe A

Klinik für Urologie, Universitätsklinikum Düsseldorf, Düsseldorf, Deutschland.

Published: November 2016

Download full-text PDF	Source
http://dx.doi.org/10.1007/s00120-016-0248-5	DOI Listing

Publication Analysis

high-risk muscle

muscle invasive

invasive urothelial

urothelial carcinoma

[adjuvant study

study high-risk

carcinoma open-label

open-label multicenter

multicenter randomized

randomized phase iii

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!